NewAmsterdam Pharma N.V.

Contributing Author

Recent Articles by NewAmsterdam Pharma N.V.

10 hours	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions NAMS GlobeNewswire
May-28	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June NAMS GlobeNewswire
May-11	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May NAMS GlobeNewswire
May-07	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NAMS +12.46% GlobeNewswire
May-01	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS +5.03% NAMS GlobeNewswire
Apr-08	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference NAMS GlobeNewswire
Apr-02	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Mar-23	NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session NAMS GlobeNewswire
Mar-06	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Feb-25	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March NAMS GlobeNewswire
Feb-18	NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update NAMS GlobeNewswire
Feb-06	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS +6.99% GlobeNewswire
Feb-04	NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit NAMS GlobeNewswire
Jan-09	NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities NAMS GlobeNewswire
Jan-05	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Dec-05	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Nov-25	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December NAMS GlobeNewswire
Nov-07	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS +6.01% NAMS GlobeNewswire
Nov-05	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results NAMS GlobeNewswire
Oct-30	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November NAMS +8.05% GlobeNewswire
Sep-24	NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum NAMS GlobeNewswire
Aug-25	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September NAMS GlobeNewswire
Aug-18	NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib NAMS GlobeNewswire
Aug-06	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results NAMS +8.70% GlobeNewswire
Jul-30	NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 NAMS GlobeNewswire
Jul-22	NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 NAMS GlobeNewswire
Jun-09	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial NAMS GlobeNewswire
Jun-05	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 NAMS GlobeNewswire
May-27	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June NAMS GlobeNewswire
May-14	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference NAMS GlobeNewswire
May-08	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NAMS GlobeNewswire
May-07	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 NAMS GlobeNewswire
May-02	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire

NewAmsterdam Pharma N.V.

Recent Articles by NewAmsterdam Pharma N.V.

Upgrade your Finviz experience